DK1501848T3 - Syntese af låst nukleinsyrederivater - Google Patents

Syntese af låst nukleinsyrederivater

Info

Publication number
DK1501848T3
DK1501848T3 DK03718663T DK03718663T DK1501848T3 DK 1501848 T3 DK1501848 T3 DK 1501848T3 DK 03718663 T DK03718663 T DK 03718663T DK 03718663 T DK03718663 T DK 03718663T DK 1501848 T3 DK1501848 T3 DK 1501848T3
Authority
DK
Denmark
Prior art keywords
lna
synthesis
nucleic acid
acid derivatives
locked nucleic
Prior art date
Application number
DK03718663T
Other languages
Danish (da)
English (en)
Inventor
Mads Detlef Sorensen
Jesper Wengel
Troels Koch
Signe M Christensen
Christoph Rosenbohm
Daniel Sejer Darwin C Pedersen
Original Assignee
Santaris Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma As filed Critical Santaris Pharma As
Application granted granted Critical
Publication of DK1501848T3 publication Critical patent/DK1501848T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK03718663T 2002-05-08 2003-05-08 Syntese af låst nukleinsyrederivater DK1501848T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200200712 2002-05-08
DKPA200201214 2002-08-16
PCT/DK2003/000305 WO2003095467A1 (en) 2002-05-08 2003-05-08 Synthesis of locked nucleic acid derivatives

Publications (1)

Publication Number Publication Date
DK1501848T3 true DK1501848T3 (da) 2007-10-22

Family

ID=29421786

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03718663T DK1501848T3 (da) 2002-05-08 2003-05-08 Syntese af låst nukleinsyrederivater

Country Status (9)

Country Link
EP (1) EP1501848B1 (de)
JP (1) JP4476802B2 (de)
AT (1) ATE369375T1 (de)
AU (1) AU2003222743B2 (de)
CA (1) CA2484526C (de)
DE (1) DE60315444T2 (de)
DK (1) DK1501848T3 (de)
ES (1) ES2290448T3 (de)
WO (1) WO2003095467A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
SI2264172T1 (sl) 2002-04-05 2017-12-29 Roche Innovation Center Copenhagen A/S Oligomerne spojine za modulacijo izražanja HIF-1alfa
EP2752488B1 (de) 2002-11-18 2020-02-12 Roche Innovation Center Copenhagen A/S Antisense-Entwurf
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
DK1606406T4 (da) 2003-03-21 2013-12-16 Santaris Pharma As Short Interfering RNA (siRNA) Analogues
AU2004303464B2 (en) 2003-12-23 2009-10-01 Santaris Pharma A/S Oligomeric compounds for the modulation of BCL-2
AU2005304112B2 (en) 2004-11-09 2009-06-04 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
WO2006050732A2 (en) 2004-11-09 2006-05-18 Santaris Pharma A/S Lna oligonucleotides and the treatment of cancer
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
ES2556128T3 (es) 2006-03-23 2016-01-13 Roche Innovation Center Copenhagen A/S ARN interfiriente pequeño internamente segmentado
NZ571569A (en) 2006-04-03 2011-09-30 Santaris Pharma As Pharmaceutical compositions comprising anti miRNA antisense oligonucleotides
CA2649045C (en) 2006-04-03 2019-06-11 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2054415A1 (de) * 2006-07-14 2009-05-06 Santaris Pharma A/S Adenosinrezeptorantagonisten
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
WO2008113830A1 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
WO2008153933A2 (en) 2007-06-06 2008-12-18 Avi Biopharma, Inc. Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
WO2009027978A1 (en) 2007-08-30 2009-03-05 Hadasit Medical Research Services & Development Ltd. NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
EP2548962B1 (de) 2007-09-19 2016-01-13 Applied Biosystems, LLC Sirna-sequenz-unabhängige Modifikationsformate zur Verringerung von das Ziel verfehlenden phänotypischen Effekten bei RNAI und stabilisierte Formen davon
WO2009043353A2 (en) 2007-10-04 2009-04-09 Santaris Pharma A/S Micromirs
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
EP2315832B1 (de) 2008-08-01 2015-04-08 Roche Innovation Center Copenhagen A/S Micro-rna-vermittelte modulation koloniestimulierender faktoren
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
WO2011009697A1 (en) 2009-07-21 2011-01-27 Santaris Pharma A/S Antisense oligomers targeting pcsk9
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
ES2631458T3 (es) 2010-03-04 2017-08-31 Interna Technologies B.V. Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
NZ719520A (en) 2010-07-06 2017-07-28 Int Tech Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
GB201012418D0 (en) 2010-07-23 2010-09-08 Santaris Pharma As Process
EP2474617A1 (de) 2011-01-11 2012-07-11 InteRNA Technologies BV MIR zur Behandlung von Neoangiogenese
EP2734553B1 (de) * 2011-07-21 2019-04-17 Rhodia Opérations hAARBEHANDLUNGSZUSAMMENSETZUNGEN ENTHALTEND KATIONISCHE GUAR-DERIVATE
LT2794627T (lt) 2011-12-22 2019-01-10 Alios Biopharma, Inc. Pakeistieji nukleozidai, nukleotidai ir jų analogai
EP3369818B1 (de) 2011-12-22 2021-06-09 InteRNA Technologies B.V. Mirna zur behandlung von kopf-hals-karzinom
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2917348A1 (de) 2012-11-06 2015-09-16 InteRNA Technologies B.V. Kombination zur behandlung von erkrankungen oder zuständen im zusammenhang mit melanom oder behandlung von erkrankungen und zuständen im zusammenhang mit aktivierten b-raf-signalweg
EP2943570B1 (de) 2013-01-14 2018-01-03 Pierfrancesco Tassone Inhibitoren von mirnas 221 und 222 zur antitumorwirkung bei multiplem myelom
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
EP3591054A1 (de) 2013-06-27 2020-01-08 Roche Innovation Center Copenhagen A/S Gegen pcsk9 gerichtete antisense-oligomere und konjugate
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
JP6867945B2 (ja) 2014-10-03 2021-05-12 コールド スプリング ハーバー ラボラトリー 核内遺伝子出力の標的とされた増強
WO2016128583A2 (en) * 2015-02-15 2016-08-18 Ribo Task Aps Acyl-amino-lna and/or hydrocarbyl-amino-lna oligonucleotides
TW201718618A (zh) * 2015-09-18 2017-06-01 田邊三菱製藥股份有限公司 架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物
WO2017060731A1 (en) 2015-10-09 2017-04-13 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
SG11201804443UA (en) 2015-12-14 2018-06-28 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
SG11201809002RA (en) 2016-04-29 2018-11-29 Univ Nanyang Tech G-quadruplex-containing antisense oligonucleotides
WO2018024849A1 (en) 2016-08-03 2018-02-08 Aalborg Universitet ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
LT3673080T (lt) 2017-08-25 2023-12-27 Stoke Therapeutics, Inc. Priešprasminiai oligomerai, skirti būklėms ir ligoms gydyti
CA3079524A1 (en) 2017-11-03 2019-05-09 Interna Technologies B.V. Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
CN111936150A (zh) 2018-02-12 2020-11-13 因特尔纳技术有限公司 抗癌微小rna及其脂质制剂
IT201900017234A1 (it) 2019-09-25 2021-03-25 Int Centre For Genetic Engineering And Biotechnology Anti-miRNA per il trattamento del leiomioma
MX2022014151A (es) 2020-05-11 2022-11-30 Stoke Therapeutics Inc Oligomeros antisentido de opa1 para tratamiento de afecciones y enfermedades.
IL304956A (en) 2021-02-12 2023-10-01 Merand Pharmaceuticals Inc Materials, compositions and methods for treating hypoxia and ischemia-related disorders
EP4313073A1 (de) 2021-03-26 2024-02-07 Neumirna Therapeutics ApS Mikrorna-134-inhibitoren
BR112023019582A2 (pt) 2021-03-26 2023-12-05 Neumirna Therapeutics Aps Oligonucleotídeo antissenso inibidor de microrna-27b
EP4347824A1 (de) 2021-06-04 2024-04-10 Neumirna Therapeutics ApS Antisense oligonukleotide gegen adenosinkinase
AU2022329834A1 (en) 2021-08-17 2024-03-07 Korea Advanced Institute Of Science And Technology Antisense oligonucleotide targeting cav3.1 gene and uses thereof
EP4388096A1 (de) 2021-08-19 2024-06-26 Neumirna Therapeutics ApS Antisense oligonukleotide gegen adenosinkinase
EP4332239A1 (de) 2022-08-30 2024-03-06 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Mir-basierter test zur diagnose und prognose von gastro-entero-pankreatischen neuroendokrinen tumoren

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178999B1 (de) * 1999-05-04 2007-03-14 Santaris Pharma A/S L-ribo-lna analoge
EP1334109B1 (de) * 2000-10-04 2006-05-10 Santaris Pharma A/S Verbesserte synthese von purin-blockierten nukleinsäure-analoga

Also Published As

Publication number Publication date
CA2484526A1 (en) 2003-11-20
EP1501848B1 (de) 2007-08-08
JP2005532319A (ja) 2005-10-27
EP1501848A1 (de) 2005-02-02
CA2484526C (en) 2009-10-13
WO2003095467A1 (en) 2003-11-20
AU2003222743B2 (en) 2008-12-11
ES2290448T3 (es) 2008-02-16
DE60315444D1 (en) 2007-09-20
ATE369375T1 (de) 2007-08-15
AU2003222743A1 (en) 2003-11-11
JP4476802B2 (ja) 2010-06-09
DE60315444T2 (de) 2008-04-30

Similar Documents

Publication Publication Date Title
DK1501848T3 (da) Syntese af låst nukleinsyrederivater
TW200503724A (en) Novel pharmaceuticals
UA95600C2 (en) Synthesis scheme for lacosamide
HK1088013A1 (en) Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
WO2008141248A3 (en) Thiocarbon-protecting groups for rna synthesis
WO2007085895A3 (en) Fap inhibitors
WO2009146218A8 (en) Compounds including an anti-inflammatory pharmacore and methods of use
MY161575A (en) Mixture for the treatment of urea-containing fertilizers
BRPI0411268B8 (pt) processo para a preparação de compostos 3-aril butil-amina substituído
GB0521508D0 (en) Organic compounds
WO2007117591A3 (en) Total synthesis of salinosporamide a and analogs thereof
TW200640912A (en) Novel processes for the preparation of a 2H-chromene
GEP20125512B (en) Process for synthesis of agomelatin
WO2009137444A3 (en) Cure accelerators for anaerobic curable compositions
WO2009137455A3 (en) Cure accelerators for anaerobic curable compositions
IL208290A0 (en) Process for the preparation of 10-deacetyl-bis-7, 10- trichloroacetylbaccatin iii
WO2007066158A3 (en) HIGH PURITY 17α-CYANOMETHYL-17β-HYDROXY-ESTRA-4,9-DIENE-3-ONE AND PROCESS FOR THE SYNTHESIS THEREOF
WO2007049295A3 (en) An improved one pot process for making key intermediate for gemcitabine hcl
DK1877370T3 (da) Fremgangsmåde til fremstilling af hydrazon-derivater
WO2011038152A3 (en) Toll-like receptor modulators and uses thereof
WO2004002990A3 (en) Synthesis of purine derivatives
GB0327323D0 (en) Novel pharmaceuticals
WO2006043175A3 (en) Process for preparing purine compounds
EP1127873A3 (de) Verfahren zur Herstellung von substituierten Benzoylcyanid Amidinohydrazonen
MX2008002112A (es) Proceso quimico.